PTO/SB/30 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number the Paperwork Reduction Act of 1995, no persons are require

Request For Continued Examination (RCE) **Transmittal**

Address to: Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

ed to respond to a collection of information diffess it displays a valid ONB control number			
Application Number	08/071,052		
Filing Date	6/4/1993		
First Named Inventor	Kreamer		
Art Unit	1614		
Examiner Name	Criares		
Attorney Docket Number	4673120/4650		

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

amendments e applicant does amendment(s) a. Previo	required under 37 CFR 1.114 Note: If the RCE is proper, an enclosed with the RCE will be entered in the order in which they we not wish to have any previously filed unentered amendment(s) enclosed. Dusly submitted. If a final Office action is outstanding, any amend dered as a submission even if this box is not checked.	ere filed unless applicant instructs otherwise. If ntered, applicant must request non-entry of such		
i ii	Consider the arguments in the Appeal Brief or Reply Brief previo	usly filed on		
b.		tion Disclosure Statement (IDS)		
2. Miscellaneo	us .			
· ·	ension of action on the above-identified application is requested u d of months. (Period of suspension shall not exceed 3 months; I	``		
3. Fees The	RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when	n the RCE is filed.		
	Director is hereby authorized to charge the following fees, or credit sit Account No. <u>12-2250</u>	t any overpayments, to		
i. 🗸	RCE fee required under 37 CFR 1.17(e)			
ii.	Extension of time fee (37 CFR 1.136 and 1.17)			
iii. 🗸	Other Petition to Revive			
b. 🗸 Chec	k in the amount of \$1,050.00	enclosed		
c. Payment by credit card (Form PTO-2038 enclosed)				
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Name (Print/Type)	Kent A. Herink	Registration No. (Attorney/Agent) 31025		
Signature	I AMOUNT IIUUM	Date / 25, 2004		

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type) Jeri D. Krutsinger

This collection of information is required by 37 CFR 0/114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Date Mau

PTO/SB/64 (11-03)

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Termin	al disclaimer with disclaime	r fee
	Since this utility/plant applic	cation was filed on or after June 8, 1995, no terminal disclaimer is required.
₹	A terminal disclaimer (and on the contract of	disclaimer fee (37 CFR 1.20(d)) of \$_10.00 for a small entity or \$ for sclaiming the required period of time is enclosed herewith (see PTO/SB/63).
filing o Traden abando	f a grantable petition und nark Office may require	in filing the required reply from the due date for the required reply until the states of the states
		this form may become public. Credit card information should not rovide credit card information and authorization on PTO-2038.
_5	125/04 Date	Censh Herring Signature
Telephone Number: 5	15-288-2500	Kent A. Herink
	10 200 2000	Typed or printed name
		The Financial Center, 666 Walnut Street, Suite 2500 Address
	_	Des Moines, Iowa 50309-3993
Enclosures:	Fee Payment	Address
	✓ Reply	
	Terminal Disclaime	Form
	Additional sheets co	ontaining statements establishing unintentional delay
•	Other: Return Postc	ard
	CERTIFICAT	E OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]
I hereby	certify that this corresponden	ce is being:
✓		States Postal Service on the date shown below with sufficient postage as ope addressed to: Mail Stop Petition , Commissioner for Patents, , VA 22313-1450.
	transmitted by facsimile on (703) 872-9306.	the date shown below to the United States Patent and Trademark Office at
	5-25-04	Just D. Krutsinger
	Date	Signature
		Jeri D. Krutsinger Typed or printed name of person signing certificate
		Typed of printed name of person signing certificate

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	Group Art Unit 1614
Kreamer)	-
)	
Serial No. 08/071,052)	Examiner: Criares
Filed: June 4, 1993)	
For: Aspirin and Vitamin and/or Trace)	
Element Compositions for the)	
Amelioration and Treatment of Vascular)	
Disease)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In the matter of the above-identified patent application, kindly enter the following amendments and consider the following remarks relative to the continued examination of the patent application.

Amendments to the claims begin on page 2 of this response.

Remarks begin on page 5 of this response.